𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapeutic use of131I-metaiodobenzylguanidine (MIBG) in neuroblastoma: A phase II study in nine patients

✍ Scribed by Hartmann, O. ;Lumbroso, J. ;Lemerle, J. ;Schlumberger, M. ;Ricard, M. ;Aubert, B. ;Coonaert, S. ;Merline, L. ;Olive, D. ;De Lumley, L. ;Parmentier, C.

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
576 KB
Volume
15
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Effects of high activities of I 131 meta-iodobenzylguanidine (mIBG) were evaluated in nine children with advanced neuroblastoma. All patients had been previously heavily treated and had either primarily refractory disease or resistant relapse. Twenty-two doses of mIBG labeled with 1.3 to 4 GBq (35-108 mCi) of iodine 131 were administered. Three subjective effects, especially relief of pain, and two objective effects were observed. Transient blood pressure increase was observed once and did not recur after prolongation of the infusion time to 6 hours. A major side effect was bone marrow toxicity, essentially marked by thrombopenia, particularly severe in previously bone-marrow-transplanted patients.

πŸ“œ SIMILAR VOLUMES

Metaiodobenzylguanidine (MIBG) labeled w
Metaiodobenzylguanidine (MIBG) labeled with123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the international workshop of pediatric oncology held in Rome, september 1986
✍ Feine, U. ;MΓΌller-Schauenburg, W. ;Treuner, J. ;Klingebiel, T H. πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 701 KB

Our experience in scintigraphic diagnosis using 123I/131I-metaiodobenzylguanidine (MIBG) on 37 children with neuroblastomas stage III-IV is reported and discussed, together with the results obtained by other authors on MIBG diagnosis at the International Workshop of Pediatric Oncology held in Rome i

Prolonged administration of low dose inf
Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study
✍ Dana S. Thompson; John D. Hainsworth; Kenneth R. Hande; Mary Holzmer; F. Anthony πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 738 KB

## Background: Etoposide displays remarkable schedule dependency. to better define the optimal dose and schedule, the authors administered etoposide as a prolonged low daily dose infusion in patients with a variety of advanced malignancies. ## Methods: Between october 1989 and april 1992, 40 pati

Ex vivo ras peptide vaccination in patie
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
✍ Marianne K. Gjertsen; Arne Bakka; Jarle Breivik; Ingvil Saeterdal; Tobias Gedde- πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 French βš– 434 KB πŸ‘ 2 views

In a pilot phase 1/11 study we have tested synthetic ras peptides used as a cancer vaccine in 5 patients with advanced pancreatic carcinoma. The treatment principle used was based on loading professional antigen-presenting cells (APCs) from peripheral blood with a synthetic ras peptide corresponding

A phase II study of adoptive immunothera
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
✍ Daniel H. Palmer; Rachel S. Midgley; Noweeda Mirza; Elizabeth E. Torr; Forhad Ah πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 286 KB

This is a phase II clinical trial investigating the safety and efficacy of intravenous vaccination with mature autologous dendritic cells (DCs) pulsed ex vivo with a liver tumor cell line lysate (HepG2) in patients with advanced hepatocellular carcinoma (HCC). HCC is an attractive target for immunot